In the Claims:

The listing of claims will replace all prior versions and listings of claims in the application.

Listings of claims:

1. (Original) A compound of Formula (I),



Formula (I)

wherein

A represents a direct bond or optionally substituted C_{1-5}alkylene;

$\mathbf{R^1}$ represents hydrogen; optionally substituted C_{1-8}alkyl; or $(CH_2)_b$-$\mathbf{R^a}$, wherein $\mathbf{R^a}$ represents C_{3-8}cycloalkyl and **b** is zero or an integer from 1 to 6;

$\mathbf{R^2}$ represents an optionally substituted mono- or bi-cyclic aromatic ring structure wherein the optional substituents are selected from cyano, $N\mathbf{R^3R^{3a}}$, optionally substituted C_{1-8}alkyl, optionally substituted C_{1-8}alkoxy or halo;

$\mathbf{R^3}$ and $\mathbf{R^{3a}}$ are independently selected from hydrogen; optionally substituted C_{1-8}alkyl and optionally substituted aryl;

R^4 is selected from an optionally substituted 3- to 8- membered heterocyclic ring containing from 1 to 4 heteroatoms independently selected from O, N and S; or a group of formula **III-a**; **III-b**; **III-c**; **III-d**; **III-e**; **III-f**, **III-g** , **III-h**, **III-i**, **III-j** or **III-k**;



III-a



III-b



III-c



III-d



III-e



III-f



III-g



III-h



III-i



III-j



III-k

wherein **het** represents an optionally substituted 3- to 8- membered heterocyclic ring containing from 1 to 4 heteroatoms independently selected from O, N and S;

R^6 and R^{6a}, are selected from:

(i) R^6 and R^{6a} are independently selected from hydrogen and optionally substituted C_{1-8}alkyl; or

(ii) R^6 and R^{6a} together represent carbonyl; or

(iii)  represents an optionally substituted 3- to 8-membered heterocyclic ring containing from 1 to 3 further heteroatoms independently selected from O, N and S, and R^{6a} represents hydrogen and optionally substituted C_{1-8}alkyl;

R^7 represents hydrogen or optionally substituted C_{1-8}alkyl;

$\mathbf{R}^8$ are selected from: : C_{1-4}alkyl, C_{2-4}alkenyl, C_{2-4}alkynyl and heterocyclyl wherein $\mathbf{R}^8$ is optionally substituted with halo, hydroxy, amino, NO_2, cyano, C_{1-4}alkanoyloxy, N-C_{1-4}alkylamino, N,N-di-C_{1-4}alkylamino, HO-C_{2-4}alkyl-NH-, HO-C_{2-4}alkyl-N(C_{1-4}alkyl)-, -$S(O_n)$-C_{1-4}alkyl, -$N(\mathbf{R})S(O_n)$-C_{1-4}alkyl, -$S(O_n)N(\mathbf{R})$-C_{1-4}alkyl or heterocyclyl optionally substituted by C_{1-4}alkyl, C_{2-4}alkenyl or C_{2-4}alkynyl, wherein $\mathbf{R}$ is hydrogen or C_{1-4}alkyl;

$\mathbf{R}^9$ is selected from:

(i) $\mathbf{R}^9$ represents hydrogen, aryl, a 3- to 10 membered heterocyclic ring or optionally-substituted C_{1-8}alkyl; and

(ii) the structure $N(\mathbf{R}^9\mathbf{R}^{10})$ represents an optionally-substituted 3- to 10 membered heterocyclic ring optionally containing from 1 to 3 further heteroatoms independently selected from O, N and S;

$\mathbf{R}^{10}$ meets the definition in option (ii) for $\mathbf{R}^9$ above or when $\mathbf{R}^9$ meets the definition in option (i) above $\mathbf{R}^{10}$ represents hydrogen or optionally substituted C_{1-8}alkyl;

$\mathbf{R}^{12}$ and $\mathbf{R}^{12a}$ are selected from:

(i) $\mathbf{R}^{12}$ and $\mathbf{R}^{12a}$ are independently selected from hydrogen or optionally substituted C_{1-8}alkyl; or

(ii) $\mathbf{R}^{12}$ and $\mathbf{R}^{12a}$ together with the carbon to which they are attached form an optionally substituted 3 to 7-membered cycloalkyl ring;

$\mathbf{R}^{13}$ and $\mathbf{R}^{14}$ are selected from:

(i) $\mathbf{R}^{13}$ is selected from hydrogen; optionally substituted C_{1-8}alkyl; optionally substituted aryl; -$\mathbf{R}^d$-Ar, where $\mathbf{R}^d$ represents C_{1-8}alkylene and Ar represents optionally substituted aryl; and optionally substituted 3- to 8- membered heterocyclic ring optionally containing from 1 to 3 further heteroatoms independently selected from O, N and S; and $\mathbf{R}^{14}$ is selected from hydrogen; optionally substituted C_{1-8}alkyl and optionally substituted aryl;

(ii) wherein R^4 represents a group of formula **III-a , III-b** or **III-i**, then the group $NR^{13}(-R^{14})$ represents an optionally substituted 3- to 8-membered heterocyclic ring optionally containing from 1 to 3 further heteroatoms independently selected from O, N and S; or

(iii) wherein R^4 represents structure **III-e**,  represents an optionally substituted 3- to 8- membered heterocyclic ring optionally containing from 1 to 4 heteroatoms independently selected from O, N and S;

n is 0 to 2;

or a salt, pro-drug or solvate thereof.

2. (Original) A compound according to Claim 1 wherein R^9 represents hydrogen, optionally substituted aryl, an optionally substituted 3- to 10 membered heterocyclic ring or optionally-substituted C_{1-8}alkyl and R^{10} represents hydrogen or optionally substituted C_{1-8}alkyl wherein the optional substituents on aryl, the heterocyclic ring and C_{1-6}alkyl are selected from: hydroxy, amino, nitro, cyano, optionally-substituted aryl, optionally substituted 3- to 8- membered heterocyclyl containing from 1 to 4 heteroatoms independently selected from O, N and S, $-O-R^b$, $C(O)NR^bR^c$, $-NR^bR^c$, $-NR^cC(O)-R^b$, $-C(O)NR^bR^c$, $-NR^cS(O_{0-2})R^b$, $-S(O_{0-2})R^b$, wherein R^b and R^c are as in Claim 1.

3. (Original) A compound according to Claim 2 wherein R^9 is a C_{1-6}alkyl group substituted by pyridyl, thienyl, piperidinyl, imidazolyl, triazolyl, thiazolyl, pyrrolidinyl, piperazinyl, morpholinyl, imidazolinyl, benztriazolyl, benzimidazolyl, pyrimidinyl, pyrazinyl, pyridazinyl, oxazolyl, furanyl, pyrrolyl, 1,3-dioxolanyl or 2-azetinyl, each of which is optionally substituted.

4. (Original) A compound according to Claim 1 wherein the structure $N(\mathbf{R}^9\mathbf{R}^{10})$ represents an optionally-substituted 3- to 10 membered heterocyclic ring optionally containing from 1 to 3 further heteroatoms independently selected from O, N and S.

5. (Original) A compound according to Claim 4 wherein the 3- to 10 membered heterocyclic ring is optionally substituted by one of more groups selected from $\mathbf{R}^{15}$ wherein $\mathbf{R}^{15}$ is selected from optionally substituted aryl, an optionally substituted 3- to 10 membered heterocyclic ring or optionally substituted C_{1-4}alkyl wherein the optional substituents on aryl, a heterocyclic ring or C_{1-6}alkyl are selected from: hydroxy, amino, nitro, cyano, optionally-substituted aryl, optionally substituted 3- to 8- membered heterocyclyl containing from 1 to 4 heteroatoms independently selected from O, N and S, -O-$\mathbf{R}^b$, $C(O)N\mathbf{R}^b\mathbf{R}^c$, $-N\mathbf{R}^b\mathbf{R}^c$, $-N\mathbf{R}^cC(O)-\mathbf{R}^b$, $-C(O)N\mathbf{R}^b\mathbf{R}^c$, $-N\mathbf{R}^cS(O_{0-2})\mathbf{R}^b$, $-S(O_{0-2})\mathbf{R}^b$, wherein $\mathbf{R}^b$ and $\mathbf{R}^c$ are as defined in Claim 1.

6. (Currently amended) A compound according to claim 1~~any one of the preceding claims~~ wherein $\mathbf{R}^4$ is selected from a group of formula **III-a** , **III-g, III-h, III-i, III-j or III-k**:



III-a



III-g



III-h



III-i



III-j



III-k

~~67.~~ (Currently amended) A compound according to claim 1~~any one of the preceding claims~~ wherein **X** and $\mathbf{R^8}$ represent either:-

(a) **X** represents N and $\mathbf{R^8}$ represents cyano or –C(O)O-$\mathbf{R^b}$; or

(b) **X** represents N and $\mathbf{R^8}$ represents hydrogen.

~~78.~~ (Currently amended) A compound according to claim 1~~any one of the preceding claims~~ wherein $\mathbf{R^2}$ is selected from an optionally substituted monocyclic aromatic ring structure wherein the optional substituents are selected from cyano, N$\mathbf{R^e R^f}$, optionally substituted $C_{1\text{-}8}$alkyl, optionally substituted $C_{1\text{-}8}$alkoxy or halo wherein $\mathbf{R^e}$ and $\mathbf{R^f}$ are independently selected from hydrogen, $C_{1\text{-}6}$alkyl or aryl.

~~89.~~ (Currently amended) A compound according to claim 1~~any one of the preceding claims~~ wherein $\mathbf{R^1}$ is hydrogen.

~~910.~~ (Currently amended) A compound selected from:

isopropyl [(1*E*)-({(2*S*)-2-[5-[2-(2-azabicyclo[2.2.2]oct-2-yl)-1,1-dimethyl-2-oxoethyl]-2-(3,5-dimethylphenyl)-1*H*-indol-3-yl]propyl}amino)(3-pyridin-4-ylpyrrolidin-1-yl)methylene]carbamate;

isopropyl [(1*E*)-({(2*S*)-2-[5-[2-(7-azabicyclo[2.2.1]hept-7-yl)-1,1-dimethyl-2-oxoethyl]-2-(3,5-dimethylphenyl)-1*H*-indol-3-yl]propyl}amino)(3-pyridin-4-ylpyrrolidin-1-yl)methylene]carbamate;

and

2-[({[(1*E*)-({(2*S*)-2-[5-[2-(2-azabicyclo[2.2.2]oct-2-yl)-1,1-dimethyl-2-oxoethyl]-2-(3,5-dimethylphenyl)-1*H*-indol-3-yl]propyl}amino)(3-pyridin-4-ylpyrrolidin-1-yl)methylene]amino}carbonyl)oxy]-2-methylpropyl acetate

or a salt, pro-drug or solvate thereof.

~~10~~11. (Cancelled)

~~11~~12. (Currently amended) A pharmaceutical formulation comprising a compound, or salt, pro-drug or solvate thereof, according to claim 1 ~~any one of Claims 1 to 9~~ and a pharmaceutically acceptable diluent or carrier.

~~12~~13. (Currently amended) A method of treating and/or preventing a sex hormone related condition in a patient, the method comprising administering~~Use of~~ a compound according to claim 1, or salt, pro-drug or solvate thereof, ~~according to~~ to the patient.~~any one of Claims 1 to 9, in the manufacture of a medicament for administration to a patient, for therapeutically treating and/or preventing a sex hormone related condition in the patient.~~

~~13~~14. (Currently amended) A process of producing a compound, or salt, pro-drug or solvate thereof, according to Claim 1, wherein the process comprises a reaction step selected from any one of steps (a) to (b):-

(a) Reaction of a compound of formula **XXXII** as follows



XXXII **XXXIII**

where **X** is a leaving group;

(b) Reaction of a compound of Formula XXXIV as follows



XXXIV XXXV

and thereafter if necessary:

i) converting a compound of the Formula (I) into another compound of the Formula (I);

ii) removing any protecting groups;

iii) forming a salt, pro-drug or solvate.